MS-STAT2

A clinical drug trial, testing whether a statin could be used to treat secondary progressive multiple sclerosis.

Condition(s)

  • Multiple sclerosis

Project type

  • Clinical drug trial

About the project

MS-STAT2 is a UK-wide phase 3 clinical drug trial that will test simvastatin, a drug used to lower cholesterol, in people with the secondary progressive form of MS (SPMS).

The research will be led by Dr Jeremy Chataway, UCL Institute of Neurology, who led the phase 2 trial into simvastatin that was published in The Lancet in 2014. It involved 140 people with secondary progressive MS and found that those taking high doses of the drug (simvastatin) had a significant reduction in the rate of brain atrophy (brain shrinkage) over two years and also had better disability scores at the end of the study. The authors concluded that high doses of simvastatin might be a treatment option for SPMS in the future.

It is hoped that the phase 3 of the MS-STAT trial will establish definitively whether simvastatin is able to slow the rate of disability progression over a three year period in people with SPMS

We hope to recruit 90 people from the Lothian area into the MS-STAT2 trial. The trial involves regular visits to the Anne Rowling Clinic to have neurological examinations, blood tests, walking distance tests and cognitive testing.

Download the patient information leaflet [PDF, 1MB]

Funder(s)

MS Society, UCL and the National Institute for Health Research

Status

Recruiting now

Contact

Dawn Lyle, Research Project Coordinator
dawn.lyle1@nhs.net
0131 465 9512

Eligibility criteria

People diagnosed with secondary progressive MS may be eligible if they:

  • are aged between 25-65
  • have an EDSS (Expanded Disability Status Scale) of between 4.0 & 6.5 aided/unaided
  • and are not currently taking a statin

Other eligibility criteria apply. Please get in touch to find out more.

×